Aurinia Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Aurinia Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 2 currently recruiting 8 completed top decile by trial count

Aurinia Pharmaceuticals: 13 sponsored US clinical trials, 2 recruiting.

Aurinia Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lupus Nephritis, with 1 trials.

Top-decile sponsor footprint

Aurinia Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 21/100

8 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 1

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

NCT07596901
RECRUITING Phase 4

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

NCT07611214
TERMINATED Phase 3

Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05962788
TERMINATED Phase 3

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05288855
COMPLETED

A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

NCT05337124
COMPLETED Phase 1

Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin

NCT05306379
COMPLETED Phase 2

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

NCT04147650
COMPLETED Phase 3

Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

NCT03597464
COMPLETED Phase 2

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

NCT03597139
TERMINATED Phase 2

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

NCT03598036
COMPLETED Phase 3

Aurinia Renal Response in Active Lupus With Voclosporin

NCT03021499
COMPLETED Phase 2

AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)

NCT02141672
COMPLETED Phase 2

Study of ISA247 (Voclosporin) in De Novo Renal Transplantation

NCT00270634

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 4
Phase 4 1

Therapeutic Areas

Lupus Nephritis 1

What is open in the Aurinia Pharmaceuticals pipeline

2 recruiting of 13 indexed (15% open); 8 completed (62%).

Phase mix: 5 late (III/IV) vs 7 early (I/II) (balanced across stages).

Top condition: Lupus Nephritis (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aurinia Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 13 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Aurinia Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%5%10%15%20% Total trials Recruiting share Aurinia PharmaceuticalsAdaptimmuneAgennixAkili Interactive LabsAlumisArrowhead Regional Medical CenterBronx VA Medical CenterCandel TherapeuticsDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Aurinia Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aurinia Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aurinia Pharmaceuticals page

13 registered trials is a research-attention snapshot, not an endorsement of Aurinia Pharmaceuticals or any single study.

  • 2 of Aurinia Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lupus Nephritis is the condition Aurinia Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lupus Nephritis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Aurinia Pharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.